AU2021381437C1 - Novel spiropyrrolidine derived antiviral agents - Google Patents
Novel spiropyrrolidine derived antiviral agentsInfo
- Publication number
- AU2021381437C1 AU2021381437C1 AU2021381437A AU2021381437A AU2021381437C1 AU 2021381437 C1 AU2021381437 C1 AU 2021381437C1 AU 2021381437 A AU2021381437 A AU 2021381437A AU 2021381437 A AU2021381437 A AU 2021381437A AU 2021381437 C1 AU2021381437 C1 AU 2021381437C1
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- compound
- mmol
- alkyl
- acetone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117170P | 2020-11-23 | 2020-11-23 | |
| US63/117,170 | 2020-11-23 | ||
| US202163142663P | 2021-01-28 | 2021-01-28 | |
| US63/142,663 | 2021-01-28 | ||
| US17/479,244 US11384090B2 (en) | 2020-11-23 | 2021-09-20 | Spiropyrrolidine derived antiviral agents |
| US17/479,530 US11352363B1 (en) | 2020-11-23 | 2021-09-20 | Spiropyrrolidine derived antiviral agents |
| US17/479,244 | 2021-09-20 | ||
| US17/479,530 | 2021-09-20 | ||
| PCT/US2021/060247 WO2022109363A1 (en) | 2020-11-23 | 2021-11-22 | Novel spiropyrrolidine derived antiviral agents |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| AU2021381437A1 AU2021381437A1 (en) | 2023-06-22 |
| AU2021381437A9 AU2021381437A9 (en) | 2024-10-10 |
| AU2021381437B2 AU2021381437B2 (en) | 2025-12-18 |
| AU2021381437C1 true AU2021381437C1 (en) | 2026-04-02 |
Family
ID=78725298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021381437A Active AU2021381437C1 (en) | 2020-11-23 | 2021-11-22 | Novel spiropyrrolidine derived antiviral agents |
Country Status (13)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2022109360A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12643905B2 (en) | 2021-07-23 | 2026-06-02 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| CN117751124B (zh) * | 2021-12-17 | 2026-07-24 | 南京药石科技股份有限公司 | 螺环氧化吲哚类化合物及其用于制备抗病毒蛋白酶抑制剂药物的用途 |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
| CA3254409A1 (en) * | 2022-03-18 | 2023-09-21 | Enanta Pharmaceuticals, Inc. | PROCESSES FOR PREPARING SUBSTITUTED SPIROOXINDOLE DERIVATIVES |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| CN116621918B (zh) * | 2022-07-20 | 2023-10-31 | 深圳信立泰药业股份有限公司 | 一种螺环化合物及其制备方法与应用 |
| CN115466189B (zh) * | 2022-09-19 | 2024-08-30 | 安徽普利药业有限公司 | 一种氨基酸及其衍生物的纯化方法 |
| IL320050A (en) * | 2022-10-06 | 2025-06-01 | Enanta Pharm Inc | Crystalline forms of SARS-anti-COV-2 compound |
| CN115894504A (zh) * | 2022-10-21 | 2023-04-04 | 深圳信立泰药业股份有限公司 | 一种冠状病毒3cl蛋白酶抑制剂及其用途 |
| EP4612156A1 (en) * | 2022-11-02 | 2025-09-10 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2024094152A1 (zh) * | 2022-11-03 | 2024-05-10 | 中国科学院上海药物研究所 | 一类螺环化合物、其制备方法及用途 |
| CN118852175A (zh) * | 2023-01-17 | 2024-10-29 | 深圳信立泰药业股份有限公司 | 一种螺环化合物晶型及其制备方法与应用 |
| CN119139307B (zh) * | 2023-12-29 | 2025-09-23 | 上海柯君医药科技有限公司 | 螺环类化合物在制备3CLpro蛋白酶抑制剂或药物中的用途 |
| CN119930495A (zh) * | 2025-01-22 | 2025-05-06 | 中国科学技术大学先进技术研究院 | 化合物及其制备方法 |
| CN120815076A (zh) * | 2025-07-28 | 2025-10-21 | 广州医科大学附属第一医院（广州呼吸中心） | Sal-0133在制备预防和/或治疗人鼻病毒感染的药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017222935A1 (en) * | 2016-06-20 | 2017-12-28 | Kansas State University Research Foundation | Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses |
| WO2018042343A2 (en) * | 2016-08-30 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds that inhibit 3c and 3cl proteases and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| US7504382B2 (en) | 2003-05-06 | 2009-03-17 | Cytovia, Inc. | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof |
| DE602004011047T2 (de) | 2003-05-13 | 2008-12-24 | Universität Zu Lübeck | Kristallstruktur von der humanen coronavirus 229e hauptproteinase und deren verwendung zur entwicklung von sars-inhibitoren |
| US20060014821A1 (en) | 2003-08-27 | 2006-01-19 | Agouron Pharmaceuticals, Inc. | Inhibitors of SARS 3C like protease |
| US7462594B2 (en) | 2003-12-31 | 2008-12-09 | Taigen Biotechnology Co., Ltd. | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases |
| WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| WO2006061714A2 (en) | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| MY160077A (en) * | 2011-01-21 | 2017-02-15 | Univ Sains Malaysia | Curcumin compounds and their preparations thereof |
| UY34094A (es) * | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| CA2850003C (en) | 2011-09-27 | 2020-01-07 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
| CA2859915A1 (en) * | 2012-01-03 | 2013-07-11 | Ruey J. Yu | N-acylpeptide derivatives and their uses |
| CA2872147A1 (en) | 2012-05-02 | 2013-11-07 | Kansas State University Research Foundation | Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses |
| WO2017035409A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2018023054A1 (en) | 2016-07-28 | 2018-02-01 | Kansas State University Research Foundation | Protease transition state inhibitor prodrugs |
| JP7691691B2 (ja) * | 2020-09-11 | 2025-06-12 | 公立大学法人横浜市立大学 | 新型コロナウイルス感染症の予防又は治療用の食品組成物、医薬品組成物、医薬部外品組成物、化粧品組成物、及び雑貨 |
| WO2022109360A1 (en) * | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
-
2021
- 2021-11-22 WO PCT/US2021/060247 patent/WO2022109363A1/en not_active Ceased
- 2021-11-22 IL IL302991A patent/IL302991A/en unknown
- 2021-11-22 UY UY0001039529A patent/UY39529A/es not_active Application Discontinuation
- 2021-11-22 MX MX2023005984A patent/MX2023005984A/es unknown
- 2021-11-22 CA CA3173333A patent/CA3173333A1/en active Pending
- 2021-11-22 KR KR1020237020684A patent/KR20230124582A/ko active Pending
- 2021-11-22 AU AU2021381437A patent/AU2021381437C1/en active Active
- 2021-11-22 CN CN202111385187.8A patent/CN114524821B/zh active Active
- 2021-11-22 JP JP2023530325A patent/JP7875859B2/ja active Active
- 2021-11-22 EP EP21209522.8A patent/EP4001279A1/en active Pending
- 2021-11-23 TW TW110143587A patent/TW202237616A/zh unknown
-
2023
- 2023-05-22 CL CL2023001476A patent/CL2023001476A1/es unknown
- 2023-06-20 CO CONC2023/0008018A patent/CO2023008018A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017222935A1 (en) * | 2016-06-20 | 2017-12-28 | Kansas State University Research Foundation | Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses |
| WO2018042343A2 (en) * | 2016-08-30 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds that inhibit 3c and 3cl proteases and methods of use thereof |
Non-Patent Citations (1)
| Title |
|---|
| Thanigaimalai, ., et al. "Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: Structure-activity relationship study." European Journal of Medicinal Chemistry, 2013, 65, p 436-447 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021381437A9 (en) | 2024-10-10 |
| JP7875859B2 (ja) | 2026-06-18 |
| IL302991A (en) | 2023-07-01 |
| CN114524821B (zh) | 2026-01-02 |
| CA3173333A1 (en) | 2022-05-27 |
| TW202237616A (zh) | 2022-10-01 |
| CN114524821A (zh) | 2022-05-24 |
| JP2023551174A (ja) | 2023-12-07 |
| EP4001279A1 (en) | 2022-05-25 |
| CO2023008018A2 (es) | 2023-07-10 |
| AU2021381437B2 (en) | 2025-12-18 |
| KR20230124582A (ko) | 2023-08-25 |
| UY39529A (es) | 2022-06-30 |
| MX2023005984A (es) | 2023-08-17 |
| CL2023001476A1 (es) | 2023-12-11 |
| WO2022109363A1 (en) | 2022-05-27 |
| AU2021381437A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021381437B2 (en) | Novel spiropyrrolidine derived antiviral agents | |
| US12540141B2 (en) | Spiropyrrolidine derived antiviral agents | |
| ES2936277B2 (es) | Peptidos funcionalizados como agentes antivirales | |
| US11352363B1 (en) | Spiropyrrolidine derived antiviral agents | |
| US11384090B2 (en) | Spiropyrrolidine derived antiviral agents | |
| US12479854B2 (en) | Spiropyrrolidine derived antiviral agents | |
| US11339170B1 (en) | Spiropyrrolidine derived antiviral agents | |
| WO2022235605A1 (en) | Novel macrocyclic antiviral agents | |
| WO2023091561A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| IL300589A (en) | Peptides that function as antiviral agents | |
| US20230115107A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| JP2022506337A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する６，７－ジヒドロ－４ｈ－ピラゾロ［１，５－ａ］ピラジンインドール－２－カルボキサミド | |
| KR20240044452A (ko) | 신규한 스피로피롤리딘 유래 항바이러스제 | |
| KR20180021820A (ko) | Ido 억제제 | |
| JP2022512870A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規尿素６，７－ジヒドロ－４ｈ－ピラゾロ［１，５－ａ］ピラジン | |
| WO2023003610A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| JP2022512873A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規尿素６，７－ジヒドロ－４ｈ－ピラゾロ［４，３－ｃ］ピリジン | |
| HK40071048A (en) | Novel spiropyrrolidine derived antiviral agents | |
| EA048496B1 (ru) | Новые противовирусные агенты на основе производных спиропирролидина | |
| HK40096316A (en) | Functionalized peptides as antiviral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 DEC 2025 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 DEC 2025 |
|
| FGA | Letters patent sealed or granted (standard patent) |